aires

A specialty pharmaceutical and medical
device company focused on developing
and commercializing best in class products
to treat gastrointestinal diseases.

A specialty pharmaceutical and medical device company focused on developing and commercializing best in class products to treat gastrointestinal diseases.
Find out more

FDA Grants Cosmo Pharmaceuticals both QIDP and Fast Track Designations for Aemcolo (Rifamycin SV MMX®) for Travelers’ Diarrhea

Upon FDA Approval, Aries Pharmaceuticals, Inc. to Lead U.S. Commercial Efforts

Aries Pharmaceuticals and Olympus Initiate Co-Promotion of Eleview™ at the American College of Gastroenterology’s World Congress

Aries Pharmaceuticals, Inc. enters co-promotion agreement in the U.S. with Olympus for Eleview™

FDA accepts New Drug Application for Methylene Blue MMX™ and sets PDUFA Date for May 21, 2018

MB MMX™ is a first-in-class drug candidate based on Cosmo Pharmaceuticals’ proprietary MMX delivery
technology.

Aries Pharmaceuticals, Inc. Shares Positive Results for Clinical Study of Eleview™ at Digestive Disease Week Annual Meeting

Novel Development in Submucosal Injection Agents Elevates Lesions to Facilitate Removal

Aries Pharmaceuticals, Inc. Launches Eleview™ for use in Gastrointestinal Endoscopic Procedures

Novel Development in Submucosal Injection Agents Elevates Lesions to Facilitate Removal

Remimazolam

An ultra-short-acting intravenous benzodiazepine sedative/anesthetic.

Rifamycin SV MMX

A non-absorbable antibiotic for the treatment of bacterial infections of the colon.

LuMeBlue™

novel application of methylene blue to stain the mucosa to discover pre-cancerous lesions and polyps

ELEVIEW™

injectable composition for use in edoscopic removal of adenomas or polyps

Visit Our Careers Page for Current Job Listings

If you want to be part of building something special – come join us!